91 related articles for article (PubMed ID: 2875910)
1. New alpha 2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients.
Kashiwagi A; Harano Y; Suzuki M; Kojima H; Harada M; Nishio Y; Shigeta Y
Diabetes; 1986 Oct; 35(10):1085-9. PubMed ID: 2875910
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
[TBL] [Abstract][Full Text] [Related]
3. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM.
Sheu WH; Jeng CY; Fuh MM; Chen YD; Reaven GM
Diabetes Care; 1995 Dec; 18(12):1582-7. PubMed ID: 8722055
[TBL] [Abstract][Full Text] [Related]
4. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM.
Luzi L; Petrides AS; De Fronzo RA
Diabetes; 1993 Dec; 42(12):1868-77. PubMed ID: 8243833
[TBL] [Abstract][Full Text] [Related]
5. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
[TBL] [Abstract][Full Text] [Related]
7. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
Gutniak M; Grill V; Efendić S
J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
[TBL] [Abstract][Full Text] [Related]
8. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
9. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men.
Ferri C; Carlomagno A; Coassin S; Baldoncini R; Cassone Faldetta MR; Laurenti O; Properzi G; Santucci A; De Mattia G
Diabetes Care; 1995 Feb; 18(2):226-33. PubMed ID: 7729302
[TBL] [Abstract][Full Text] [Related]
10. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Abdel-Zaher AO; Ahmed IT; El-Koussi AD
Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
[TBL] [Abstract][Full Text] [Related]
11. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.
McMahon M; Marsh HM; Rizza RA
Diabetes; 1989 Mar; 38(3):291-303. PubMed ID: 2492963
[TBL] [Abstract][Full Text] [Related]
12. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes.
Chen YD; Jeng CY; Hollenbeck CB; Wu MS; Reaven GM
J Clin Invest; 1988 Jul; 82(1):21-5. PubMed ID: 3292584
[TBL] [Abstract][Full Text] [Related]
14. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.
Simonson DC; Delprato S; Castellino P; Groop L; DeFronzo RA
Diabetes; 1987 Feb; 36(2):136-46. PubMed ID: 3100365
[TBL] [Abstract][Full Text] [Related]
15. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes.
Revers RR; Fink R; Griffin J; Olefsky JM; Kolterman OG
J Clin Invest; 1984 Mar; 73(3):664-72. PubMed ID: 6368585
[TBL] [Abstract][Full Text] [Related]
16. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Scheen AJ; Paolisso G; Salvatore T; Lefèbvre PJ
Diabetes Care; 1991 Apr; 14(4):325-32. PubMed ID: 2060435
[TBL] [Abstract][Full Text] [Related]
17. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
[TBL] [Abstract][Full Text] [Related]
18. How insulin resistant are patients with noninsulin-dependent diabetes mellitus?
Reaven GM; Chen YD; Donner CC; Fraze E; Hollenbeck CB
J Clin Endocrinol Metab; 1985 Jul; 61(1):32-6. PubMed ID: 3889039
[TBL] [Abstract][Full Text] [Related]
19. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
Basu R; Basu A; Nielsen M; Shah P; Rizza RA
J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
[TBL] [Abstract][Full Text] [Related]
20. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM.
Bonadonna RC; Del Prato S; Bonora E; Saccomani MP; Gulli G; Natali A; Frascerra S; Pecori N; Ferrannini E; Bier D; Cobelli C; DeFronzo RA
Diabetes; 1996 Jul; 45(7):915-25. PubMed ID: 8666143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
